Litigation Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

« Back to Dashboard

Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-02-26
Court	District Court, D. Delaware	Date Terminated	2016-09-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,318,800; 8,410,167; 8,602,215
Link to Docket	External link to docket

Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-02-26				External link to document

Sanofi v. Watson Laboratories, Inc. 1:14-cv-00265: Litigation Summary and Patent Analysis

Last updated: October 5, 2026

Sanofi v. Watson Laboratories, Inc., No. 1:14-cv-00265, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Watson's abbreviated new drug application for a generic version of Sanofi's multiple-sclerosis drug Aubagio, whose active ingredient is teriflunomide. Sanofi asserted U.S. Patent No. 8,410,131, directed to methods of treating multiple sclerosis with teriflunomide. The Federal Circuit affirmed the judgment for Sanofi, preserving the asserted patent against Watson's ANDA product. [1]

What drug and patent were at issue in Sanofi v. Watson?

The case concerned Aubagio, an oral multiple-sclerosis therapy containing teriflunomide.

Item	Detail
Brand drug	Aubagio
Active ingredient	Teriflunomide
Innovator	Sanofi
Generic applicant	Watson Laboratories, Inc., later associated with Actavis/Teva
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-00265
Statutory basis	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Asserted patent	U.S. Patent No. 8,410,131
Patent subject matter	Methods of treating multiple sclerosis with teriflunomide
Appellate decision	Sanofi v. Watson Laboratories, Inc., 875 F.3d 636 (Fed. Cir. 2017)

Sanofi filed the action after Watson notified Sanofi of an ANDA containing a Paragraph IV certification challenging the asserted patent. The lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). [1]

What patent did Sanofi assert against Watson?

Sanofi asserted U.S. Patent No. 8,410,131, titled "Methods of treating multiple sclerosis." The patent claims the use of teriflunomide for treating multiple sclerosis, including administration at therapeutically effective dosages.

The litigation was important because the patent did not depend solely on a composition-of-matter claim covering teriflunomide. Sanofi relied on method-of-use protection directed to the clinical application of the active ingredient.

U.S. Patent No. 8,410,131

Patent attribute	Detail
Patent number	8,410,131
Assignee	Sanofi-related entity
Technology	Teriflunomide treatment methods
Therapeutic field	Multiple sclerosis
Filing history	Continuation and priority claims associated with Sanofi's teriflunomide program
Asserted against	Watson's generic teriflunomide ANDA
Litigation result	Upheld on appeal

The patent's commercial value came from its relationship to Aubagio's approved indication. A generic applicant could challenge the patent through Paragraph IV certification, but a successful challenge would have required invalidating the patent, establishing noninfringement, or both.

What were Watson's Paragraph IV arguments?

Watson challenged the asserted patent on invalidity and noninfringement grounds. The Federal Circuit opinion addressed the central validity issues and affirmed the district court's judgment in Sanofi's favor.

The principal legal issues included:

1. Whether the asserted claims were obvious over the prior art.
2. Whether the prior art provided a reason to select teriflunomide and the claimed treatment regimen.
3. Whether the evidence supported the claimed therapeutic effects.
4. Whether the patent's disclosure adequately supported the claimed methods.
5. Whether Watson's proposed generic product would infringe the asserted claims.

The Federal Circuit rejected Watson's challenge. The decision confirmed that the obviousness analysis had to consider the claimed treatment method as a whole rather than treating the active ingredient, disease indication, dosage, and expected result as isolated elements. [1]

How did the Federal Circuit decide Sanofi v. Watson?

The Federal Circuit affirmed the district court's judgment for Sanofi in 2017. The court held that Watson had not established that the asserted claims were invalid for obviousness.

The opinion applied the framework established in Graham v. John Deere and KSR v. Teleflex. The relevant inquiry was whether a skilled artisan would have had a reason to arrive at the claimed teriflunomide treatment method with a reasonable expectation of success. [1]

The Federal Circuit treated the clinical and pharmacological evidence as relevant to the obviousness analysis. The court did not accept a theory that the claimed method was obvious merely because teriflunomide was known and multiple sclerosis was a known disease target.

Core appellate holding

The Federal Circuit's decision preserved the patent claims against Watson's ANDA product. The ruling prevented Watson from obtaining FDA approval for the proposed generic product during the remaining enforceable term of the patent, subject to any later settlement, license, or regulatory development.

The case is regularly cited for the proposition that an obviousness analysis must evaluate the claimed therapeutic method in its complete context. Known individual components do not automatically make a claimed drug-treatment method obvious.

What was the litigation timeline?

Date	Event
March 2014	Sanofi filed the Delaware action against Watson
2014	Watson's ANDA and Paragraph IV challenge formed the basis for the case
2014-2016	District-court claim-construction, validity, and infringement proceedings
Before 2017	District court entered judgment favoring Sanofi
November 2017	Federal Circuit issued its decision in 875 F.3d 636
After appellate decision	The asserted patent remained enforceable against Watson's ANDA product unless altered by later settlement, license, or regulatory action

The 30-month stay associated with Sanofi's patent litigation delayed FDA approval while the case proceeded. The stay did not itself determine the ultimate patent term or guarantee continued market exclusivity after the patent expired.

What was the Orange Book status of Aubagio?

Aubagio's Orange Book protection consisted of listed patents covering the product and its approved use. The relevant regulatory and patent position included:

Regulatory issue	Analysis
NDA	Aubagio was approved by FDA for relapsing forms of multiple sclerosis
ANDA	Watson pursued a generic teriflunomide product
Certification	Watson used a Paragraph IV certification against Sanofi's patent position
Litigation consequence	Sanofi's lawsuit invoked the 30-month FDA approval stay
Listed patent type	Method-of-use and related product protection
Regulatory exclusivity	FDA exclusivity was separate from patent exclusivity
Generic approval	Depended on resolution of patent barriers, exclusivity periods, and FDA requirements

A Paragraph IV certification does not mean that the generic applicant will prevail. It creates a justiciable patent dispute and permits the innovator to sue before commercial launch.

Did the case involve formulation patents?

The reported appellate dispute centered on method-of-use claims for treating multiple sclerosis with teriflunomide. It was not principally a dispute over a tablet coating, controlled-release system, excipient combination, device, or other formulation technology.

That distinction matters commercially. A generic applicant may avoid a formulation patent by using a different excipient system or manufacturing process. Avoiding a method-of-use patent is more difficult when the generic label and FDA-approved indication directly correspond to the patented treatment method.

The strength of Sanofi's position therefore came from the alignment between:

• Aubagio's approved indication.
• The claimed teriflunomide treatment method.
• Watson's proposed generic labeling.
• The clinical use expected from the ANDA product.

Did the case involve biosimilar risk?

No. This was a conventional small-molecule Hatch-Waxman case, not a biologics case under the Biologics Price Competition and Innovation Act.

Teriflunomide is a chemically defined small molecule. The relevant competitive threat was a generic ANDA, not a biosimilar application. The litigation framework therefore involved Paragraph IV certification, the 30-month stay, and generic approval under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

What was the commercial impact of the decision?

The decision protected Sanofi's Aubagio franchise from Watson's proposed generic product during the enforceable life of the asserted patent.

The commercial effects were:

1. Watson could not rely on its ANDA alone to launch at risk.
2. Sanofi retained leverage in settlement or licensing negotiations.
3. The patent decision supported continued branded pricing and market share.
4. Other generic applicants faced the same patent and regulatory barriers unless they developed a distinct noninfringement or invalidity position.
5. The decision reduced the immediate probability of generic erosion for Aubagio.

The ruling did not create perpetual exclusivity. Once patent and regulatory barriers expired, multiple generic manufacturers could enter if FDA approval requirements were satisfied.

How strong was Sanofi's patent position?

Sanofi's position was strong against Watson because it survived district-court scrutiny and Federal Circuit review. The appellate affirmance materially increased the expected cost of a similar Paragraph IV challenge.

Strengths

• The asserted patent covered the approved therapeutic use.
• The litigation produced a favorable district-court judgment.
• The Federal Circuit affirmed the validity result.
• Watson's ANDA created a direct infringement theory based on the proposed use and labeling.
• The case established favorable appellate precedent for the claimed treatment method.

Limitations

• The protection was limited by the patent's statutory term.
• Method-of-use claims can be vulnerable if a generic label omits the patented indication or if the generic can establish a noninfringing use.
• Other generic applicants were not necessarily bound by every factual position taken by Watson.
• FDA approval, patent expiry, pediatric exclusivity, and any settlement terms remained separate issues.

The case was therefore a strong litigation result, but not an unlimited barrier to generic competition.

Were there licensing or settlement agreements?

The reported Federal Circuit decision addressed the merits of the Sanofi-Watson dispute. Publicly available appellate materials do not establish a later commercial settlement that superseded the judgment.

Any confidential or later agreement would need to be evaluated separately from the appellate opinion. A settlement could have included a defined generic launch date, a license, a no-challenge provision, supply terms, or a release of infringement claims. The appellate decision itself should not be treated as evidence of a settlement.

What generic launch scenarios existed after the ruling?

Three principal launch scenarios applied.

Authorized or licensed entry

Sanofi could grant Watson a license to launch before patent expiry. The commercial terms could include royalties, volume restrictions, or a negotiated entry date.

Post-expiry entry

Watson could launch after expiration of the enforceable patent term and any applicable pediatric exclusivity, provided FDA approval was in effect.

At-risk launch

Watson could launch before final patent resolution at the risk of damages and injunctive relief. The Federal Circuit's affirmance made this option commercially less attractive.

The most probable practical result after the appellate decision was delayed entry until a license, settlement, or patent-term endpoint permitted commercialization.

What patent litigation affected Aubagio competitors?

Sanofi's favorable result against Watson affected the risk assessment for other ANDA applicants. Competitors would need to evaluate:

• Whether their product infringed the asserted method claims.
• Whether their labeling included the patented indication.
• Whether they could establish anticipation or obviousness using different prior-art evidence.
• Whether the Orange Book listing was properly submitted.
• Whether the 30-month stay had expired or been terminated.
• Whether Sanofi had entered a settlement with another applicant.

The ruling did not automatically resolve every later Aubagio case. Each ANDA applicant could present different formulation, labeling, dosage, or invalidity arguments.

Key Takeaways

• Sanofi v. Watson Laboratories, No. 1:14-cv-00265, concerned generic teriflunomide for Aubagio.
• Sanofi asserted U.S. Patent No. 8,410,131, covering methods of treating multiple sclerosis.
• Watson pursued a Paragraph IV challenge under the Hatch-Waxman Act.
• The district court ruled for Sanofi.
• The Federal Circuit affirmed in Sanofi v. Watson Laboratories, 875 F.3d 636 (Fed. Cir. 2017).
• The case strengthened Sanofi's position against Watson's proposed generic launch.
• The dispute involved small-molecule generic competition, not biosimilar substitution.
• The asserted protection was primarily method-of-use protection rather than a formulation or manufacturing patent.
• The appellate ruling did not extend exclusivity beyond the patent's statutory term.
• Any later settlement or license must be analyzed separately from the appellate merits decision.

FAQs

What was Sanofi's drug in the Watson patent case?

The case involved Aubagio, Sanofi's teriflunomide product for relapsing forms of multiple sclerosis.

What type of patent challenge did Watson file?

Watson filed a Paragraph IV certification challenging Sanofi's listed patent protection as part of its ANDA process.

Did Watson win the Sanofi patent litigation?

No. The Federal Circuit affirmed the judgment favoring Sanofi and upheld the asserted patent against Watson's challenge.

Was Sanofi v. Watson a biologics patent case?

No. It was a Hatch-Waxman case involving a small-molecule generic drug application.

Did the decision permanently block generic teriflunomide?

No. It delayed or restricted Watson's proposed launch during the enforceable patent period. It did not prevent generic entry after patent and regulatory barriers expired.

References

1. Sanofi v. Watson Laboratories, Inc., 875 F.3d 636 (Fed. Cir. 2017).

2. U.S. District Court for the District of Delaware. (2014). Sanofi v. Watson Laboratories, Inc., No. 1:14-cv-00265, docket records.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (n.d.). Aubagio approval history. Drugs@FDA.

5. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.